About Genmab

Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged transactional research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030 Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO®) antibody medicines.

How we Operate

Team: Flexible and adaptive infrastructure

Research: Track record of success and investing for tomorrow

Development: Scaling up capabilities to expand from early-to-late stage

Commerilzation: Next step in our evolution

Translational Research & Data Science: Key to accelerating development & ensuring the right therapies get to the right patients

Enabling Functions: support growth and manage risk

Strong financials: Growing recurring revenues and focused investment

Collaboration: Across innovation ecosystem of pharma, biotech & academia, drives our business forward

At-a-glance

Genmab’s Growing Organization & Presence

Princeton, USA
- Translational and Quantitative Sciences
- Clinical Developments
- Development Operations
- U.S. Market Operations
- Corporate Functions

Copenhagen, Denmark
- Headquarters
- Translational and Quantitative Sciences
- Chemistry, Manufacturing and Controls (CMC) Operations
- Development Operations
- Quality Control Laboratory
- Corporate Functions

Utrecht, The Netherlands
- Discovery and Antibody Research
- Translational and Quantitative Sciences
- Development Operations
- Corporate Functions

Tokyo, Japan
- Development Operations
- Japan Market Operations
- Corporate Functions

2023 Financials (DKK)

- 142B Year-end market cap
- 5,321M Operating Profit
- 16,474M Revenue
- 10,927M Operating Expenses 70% in R&D

Cumulative INDs since 1999

Created by Genmab or with Genmab’s technologies

Our Purpose

Our unstoppable team will improve the lives of patients through innovative and differentiated antibody therapeutics.

Our Vision

By 2030, our KYSO antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases.

Our Values

- Passion for innovation
- Determined - being the best at what we do
- Integrity - we do the right thing
- We work as one team & respect each other

Our Strategy

- Focus on core competence
- Turn science into medicine
- Build a profitable and successful biotech

Operational

Approved Medicines Including Genmab’s Innovation

Tivdak®, first Genmab owned product on market. Genmab owned, co-developed and co-promoted in partnership with Pfizer**
EPIKINLY®/TEPKINLY® in partnership with AbbVie, second Genmab owned product on market
DARZALEX®, RYBREVANT®, TECVAYL®, and TALVEZ® discovered and/or developed & marketed by Janssen
Kesimpta® developed & marketed by Novartis
TEPEZZA® developed & marketed by Horizon Therapeutics

Proprietary* Technologies

DuoBody®platform, HexaBody® platform, DuoHexaBody® platform & HexElect® platform

Proprietary* Antibody Products in Clinical Development

Tisotumab vedotin, epcoritamab, DuoBody-PO-L1x4-1BB (GEN1046/BNT311), DuoBody-CD4x4-1BB (GEN1042/BNT312), DuoBody-CD27x4-1BB (GEN1056/BNT313), DuoBody-CD27x4-1BB (GEN3009), DuoBody-CD27x4-1BB (GEN3014), DuoBody-CD3x1/B7H4 (GEN1047)

Our Strengths & Differentiators

- World-Class antibody biology knowledge and deep insight into disease targets
- Discovery and development engine with proprietary technologies that allow us to build a world-class pipeline
- In-house expertise with solid track record of building successful strategic partnerships
- Pipeline of potential best-in-class and first-in-class therapies
- Experienced, diverse leadership team

Translational Research & Data Science:

Key to accelerating development & ensuring the right therapies get to the right patients

Translation Research & Data Science:

Key to accelerating development & ensuring the right therapies get to the right patients

Translation Research & Data Science:

Key to accelerating development & ensuring the right therapies get to the right patients
### Strong Pipeline of Potential 1st-in-class/Best-in-class Product Candidates

#### Innovative Pipeline: Genmab’s Proprietary Products

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Developed by</th>
<th>Disease Indications</th>
<th>Most Advanced Development Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trastuzumab vedotin</td>
<td>Co-developed Genmab /Seagen</td>
<td>Breast cancer</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>Enfortumab</td>
<td>Co-developed Genmab /Alphatec</td>
<td>Urothelial cancer</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>Ancellitasib (GEN1048-EN10)</td>
<td>Co-developed Genmab /Bulet Tech</td>
<td>Solid tumors</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>DuoBody-CD40x4-1BB (GEN1031)</td>
<td>Co-developed Genmab /Bulet Tech</td>
<td>Solid tumors</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>HexaBody-CD38 (GEN1030)</td>
<td>Genmab</td>
<td>Solid tumors</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>DuoHexaBody (GEN1031)</td>
<td>Co-developed Genmab /Bulet Tech</td>
<td>Solid tumors</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>HexaBody-CD38 (GEN1031)</td>
<td>Co-developed Genmab /Bulet Tech</td>
<td>Solid tumors</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>HexaBody-CD38 (GEN1031)</td>
<td>Co-developed Genmab /Bulet Tech</td>
<td>Solid tumors</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>LumaPEG2222 (LUMA-PEG2222)</td>
<td>LumaBiotec</td>
<td>Multiple system atrophy</td>
<td>Pre-clinical 1</td>
</tr>
</tbody>
</table>

### Proprietary Technologies Allow us to Build a World-class Pipeline

**DuoBody Platform**
- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases and hemophilia
- Multiple commercial & research collaborations

**HexaBody Platform**
- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

**DuoHexaBody Platform**
- Antibody technology that combines DuoBody and HexaBody platforms
- Creates bispecific antibodies with target mediated enhanced potency

**HexElect Platform**
- Antibody technology platform inspired by HexaBody platform
- Combines dual targeting with enhanced selectivity & potency

### Executive Management

- Jan G. J. van de Winkel, Ph.D., President & CEO
- Anthony Pagano, EVP & CFO
- Judith Klimovsky, M.D., EVP & CDO
- Anthony Mancini, EVP & COO
- Tahamtan Ahmadi, M.D., Ph.D., EVP & CMO
- Birgitte Stephensen, EVP & CLO
- Christopher Cozic, EVP & CPO
- Martine J. van Vught, Ph.D., EVP & CSO

### Programs Incorporating Genmab’s Innovation and Technology, >Phase 2 Development

<table>
<thead>
<tr>
<th>Product</th>
<th>Technology</th>
<th>Disclosed and/or Developed By</th>
<th>Disease Indications</th>
<th>Most Advanced Development Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carotidumin</td>
<td>UMBAD*</td>
<td>Janssen</td>
<td>Multiple myeloma</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>Teprotumumab</td>
<td>UMBAD</td>
<td>Amgen</td>
<td>AL Amyloidosis</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>Amivantumab</td>
<td>DuoBody</td>
<td>Janssen</td>
<td>Thyroid eye disease</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>Tesokizumab</td>
<td>DuoBody</td>
<td>Janssen</td>
<td>Advanced or metastatic gastric or esophagus cancer</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>Telquetumab</td>
<td>DuoBody</td>
<td>Janssen</td>
<td>Relapsed or refractory multiple myeloma</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>Herceptumab</td>
<td>UMBAD</td>
<td>Novo Nordisk</td>
<td>Hepatitis A</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>Minil</td>
<td>UMBAD</td>
<td>Provenance Bio</td>
<td>Celiac disease</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>Orfodoximab (PHN-001MAO 714)</td>
<td>UMBAD</td>
<td>Pfizer</td>
<td>Vasculo-occlusive crises in sickle cell disease</td>
<td>Pre-clinical 1</td>
</tr>
<tr>
<td>Lu APER2222</td>
<td>UMBAD</td>
<td>LumaBiotec</td>
<td>Multiple system atrophy</td>
<td>Pre-clinical 1</td>
</tr>
</tbody>
</table>

**Notes:**
- Trastuzumab vedotin 50:50 partnership with Pfizer; epcoritamab 50:50 partnership with AbbVie; DuoBody-PO-1x4-1BB, DuoBody-CD40x4-1BB, HexaBody-CD27 and GEN1056 50:50 partnership with BioNTech; HexaBody-CD38, exclusive worldwide license and option agreement with Janssen Biotech, Inc.
- Pfizer acquired Seagen in December 2023
- Certain product candidates in development with partners, as noted
- 26Srab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc.
- 3Products discovered and/or developed and marketed by others incorporating Genmab technology and innovation.

This document contains forward looking statements that involve significant risks and uncertainties. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on [www.genmab.com](http://www.genmab.com) and the risk factors included in Genmab’s most recent Annual Report on form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at [www.sec.gov](http://www.sec.gov).

**February 13, 2024**